Brokerage Firm Rating on NuVasive (NUVA)

NuVasive (NUVA) : 15 analysts are covering NuVasive (NUVA) and their average rating on the stock is 1.27, which is read as a Strong Buy. 13 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 1, which recommends a Strong Buy affirms that they expect a large upside in the stock from the current levels. A total of 2 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.

NuVasive (NUVA) : 12 investment research analysts covering NuVasive (NUVA) have an average price target of $67.33 for the near short term. The highest target price given by the Brokerage Firm to the stock is $77 and the lowest target is $58 for the short term. Analysts expect the variance to be within $6.24 of the average price.


For the current week, the company shares have a recommendation consensus of Buy. NuVasive (NASDAQ:NUVA): The stock opened at $62.59 on Thursday but the bulls could not build on the opening and the stock topped out at $62.86 for the day. The stock traded down to $62.26 during the day, due to lack of any buying support eventually closed down at $62.42 with a loss of -0.34% for the day. The stock had closed at $62.63 on the previous day. The total traded volume was 221,167 shares.

In a related news, The director, of Nuvasive Inc, Howe Lesley H had unloaded 3,602 shares at $62.44 per share in a transaction on August 2, 2016. The total value of transaction was $224,909. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.

Nuvasive, Inc. is a global medical device company in the spine market. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine. Its marketed product portfolio is focused on applications for spine fusion surgery. Its product offering includes a minimally-disruptive surgical platform called Maximum Access Surgery (MAS). The MAS platform combines three categories of solutions that collectively minimize soft tissue disruption during spine fusion surgery, provide visualization and are designed to enable reproducible outcomes for the surgeon and the patient. The platform includes the Companys software-driven nerve detection and avoidance systems, including NVM5 and NVJJB, Intra-Operative Monitoring (IOM) services and support; MaXcess, which is an integrated split-blade retractor system, and a variety of implants and biologics.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.